Clinical Response to Tocilizumab in Severe Thyroid Eye Disease.
Tocilizumab, in a preliminary study, was reported to be an effective therapy for moderate to severe thyroid eye disease. The authors describe the clinical response of 2 severe thyroid eye disease cases refractory to intravenous steroids and orbital decompression. Both patients demonstrated improved clinical activity scores with minimal side effects after tocilizumab therapy. In addition, post tocilizumab orbital fat biopsies demonstrated benign adipose tissue without evidence of inflammatory cells.
Department of Ophthalmology, California Pacific Medical Center, San Francisco, California, U.S.A.
Aileen
A
Sy
Kasra
K
Eliasieh
Rona Z
RZ
Silkiss
D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001706:Biopsy; D019299:Decompression, Surgical / Q000379:methods; D005500:Follow-Up Studies; D049970:Graves Ophthalmopathy / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D012720:Severity of Illness Index
D061067:Antibodies, Monoclonal, Humanized; C502936:tocilizumab